EICHORCondition: AML, Adult · Sponsor: French Innovative Leukemia Organisation
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This observational epidemiological study targets patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive receive intensive induction therapy as defined by the group. The main aim of the study is to determine the epidemiological characteristics of AML patients, both clinically and biologically, and to correlate these to their outcome. The incidence of AML increases with age, exponentially after the age of 50, giving a median age at diagnosis of close to 70 years, with over half of patients half of patients are over 60 at diagnosis. The principle of treatment as in younger patients, is based on trying to achieve complete remission (CR). remission (CR). Observed complete remission rates range from 38 to 70%. Long-term survival of elderly subjects remains limited, at around 10 to 15%, despite the various types of consolidation tried out in recent years. years. However, intensive chemotherapy remains the preferred option for initial treatment of these hematological diseases when general condition and comorbidities allow. As shown by Swedish registry studies, it is associated with improved life expectancy. The proportion of patients who can receive intensive initial treatment is not well known in France, probably varies widely from one region to another, and certainly decreases with increasing age. Only the registry studies currently underway will enable us to assess this precisely.
This description comes directly from the study's public registry record.
Ariane Mineur · +33 (5)57 62 31 08 · ariane.mineur@chu-bordeaux.fr
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients aged 60 and over * Patients with previously untreated de novo or secondary AML * Patients suitable for standard intensive treatment * Patients who have read the information document and agreed to the collection of data concerning them (signature of informed consent). Exclusion Criteria: * Patients with AML 3 * Patients with severe, uncontrolled infection at the time of inclusion * Patients with psychiatric or social disorders that will prevent compliance with the protocol * Patients without health insurance (affiliation to a social security scheme)
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Angers CHU | Angers, France | Recruiting |
| Annecy CH | Annecy, France | Recruiting |
| Avignon CH | Avignon, France | Recruiting |
| Bayonne CH | Bayonne, France | Recruiting |
| Besançon CHU | Besançon, France | Recruiting |
| Brest CHU | Brest, France | Recruiting |
| CHU Estaing | Clermont-Ferrand, France | Recruiting |
| Colmar CH | Colmar, France | Recruiting |
| Grenoble CHU | Grenoble, France | Recruiting |
| Marseille IPC | Marseille, France | Recruiting |
| METZ-THIONVILLE CHR- Hôpital de Mercy | Metz, France | Recruiting |
| Montpellier - Chu Saint Eloi | Montpellier, France | Recruiting |
+ 15 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06891144